ATE543507T1 - Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung - Google Patents

Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung

Info

Publication number
ATE543507T1
ATE543507T1 AT08847868T AT08847868T ATE543507T1 AT E543507 T1 ATE543507 T1 AT E543507T1 AT 08847868 T AT08847868 T AT 08847868T AT 08847868 T AT08847868 T AT 08847868T AT E543507 T1 ATE543507 T1 AT E543507T1
Authority
AT
Austria
Prior art keywords
sdf
composition containing
sustained release
release composition
present
Prior art date
Application number
AT08847868T
Other languages
English (en)
Inventor
Yasuhiko Tabata
Original Assignee
Ono Pharmaceutical Co
Yasuhiko Tabata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co, Yasuhiko Tabata filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE543507T1 publication Critical patent/ATE543507T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT08847868T 2007-11-07 2008-11-06 Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung ATE543507T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007289598 2007-11-07
PCT/JP2008/003204 WO2009060608A1 (ja) 2007-11-07 2008-11-06 Ｓｄｆ－１を含有してなる徐放性組成物

Publications (1)

Publication Number Publication Date
ATE543507T1 true ATE543507T1 (de) 2012-02-15

Family

ID=40625516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08847868T ATE543507T1 (de) 2007-11-07 2008-11-06 Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung

Country Status (6)

Country Link
US (2) US8435953B2 (de)
EP (1) EP2218459B1 (de)
JP (1) JP5248519B2 (de)
AT (1) ATE543507T1 (de)
ES (1) ES2378918T3 (de)
WO (1) WO2009060608A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
JP6145089B2 (ja) * 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法
CA2846033A1 (en) 2011-08-23 2013-02-28 Mochida Pharmaceutical Co., Ltd Composition for regeneration of cartilage
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
US10420818B2 (en) 2014-05-08 2019-09-24 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
JP6532141B2 (ja) * 2014-09-26 2019-06-19 ヘリックスミス カンパニー リミテッド 肝細胞増殖因子及びストローマ細胞由来因子１αを用いた末梢動脈疾患の予防または治療用組成物
US10696974B2 (en) 2014-12-23 2020-06-30 Ilya Pharma Ab Methods for wound healing
WO2018183625A1 (en) * 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
US11654181B2 (en) 2017-08-11 2023-05-23 Wake Forest University Health Sciences Use of CXCL12 for therapy after prostate surgery
CN113144283B (zh) * 2021-04-26 2022-06-28 广东海洋大学 一种促进创伤愈合的TSCP-GelMA水凝胶及其制备和应用
WO2024220980A2 (en) * 2023-04-20 2024-10-24 The Schepens Eye Research Institute, Inc. Dscam inhibitory nucleic acids and methods of use thereof
CN120585788B (zh) * 2025-06-14 2025-12-05 山东润君药业有限公司 一种稳定性载药微胶囊及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2566798B1 (fr) * 1984-06-27 1986-12-12 Centre Nat Rech Scient Membrane porteuse de la luciferase pour le dosage de l'atp et son procede de production
EP0702959B1 (de) 1993-05-31 2001-08-08 Kaken Pharmaceutical Co., Ltd. Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
US6297337B1 (en) * 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
DE60229399D1 (de) 2001-07-18 2008-11-27 Medgel Corp Hgf-hydrogel-zubereitungen mit verzögerter freisetzung
GB0201674D0 (en) * 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
JP2004123650A (ja) * 2002-10-04 2004-04-22 Medgel Corp Ｎｋ４を含有する徐放性製剤
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
AU2005251814A1 (en) 2004-06-07 2005-12-22 Innovational Holdings, Llc Local delivery of growth factors for stem cell transplantation
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
EP1803464A4 (de) 2004-09-17 2009-09-09 Cellgentech Inc Topisches präparat zur behandlung von hautgeschwüren
US7930013B2 (en) 2005-06-29 2011-04-19 Compumedics Limited Sensor assembly with conductive bridge
JP2007182407A (ja) 2006-01-10 2007-07-19 Medgel Corp 徐放性ハイドロゲル製剤
JP2007289598A (ja) 2006-04-24 2007-11-08 Sanada Seiko Kk 食器収納器具

Also Published As

Publication number Publication date
EP2218459A1 (de) 2010-08-18
US20130243824A1 (en) 2013-09-19
US8435953B2 (en) 2013-05-07
EP2218459B1 (de) 2012-02-01
EP2218459A4 (de) 2011-06-01
US20100267612A1 (en) 2010-10-21
JPWO2009060608A1 (ja) 2011-03-17
JP5248519B2 (ja) 2013-07-31
ES2378918T3 (es) 2012-04-19
US9107953B2 (en) 2015-08-18
WO2009060608A1 (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
ATE543507T1 (de) Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
CY1112281T1 (el) Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη
CY1118887T1 (el) Φαρμακευτικες συνθεσεις ελεγχομενης αποδεσμευσης οι οποιες περιλαμβανουν εναν εστερα φουμαρικου οξεος
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
MX2013001749A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
CL2011000663A1 (es) Compuestos derivados de n-heterociclil-2-sulfonil acetamida, moduladores del receptor cb2, utiles para el tratamiento del dolor, enfermedad pulmonar, reumatica, autoinmune, entre otras.
FR2892923B1 (fr) Utilisatiion des derives de l'acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques.
EA200870019A1 (ru) Лактамовые соединения и способы их применения
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EP1874334A4 (de) Zusammensetzungen mit von beta 2-glykoprotein i stammenden peptiden zur prävention und/oder behandlung von gefässerkrankungen
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
AR050717A1 (es) Composiciones farmaceuticas
ATE413865T1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
NO20076405L (no) Anvendelse av 24-nor-UDCA
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
EA200600782A1 (ru) Терапевтические применения вариантов хемокинов
EP1781277A4 (de) Kombinationspräparat